WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending five upcoming investor conferences.

• The UBS Global Healthcare Conference, being held November 10 – 12 in Palm Beach Gardens, FL. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion at 11:00 a.m. ET on Monday, November 10.
• The Stifel Healthcare Conference, being held November 11 – 13 in New York. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst-led discussion at 10:00 a.m. ET on Tuesday, November 11.
• The Wolfe Research Healthcare Conference, being held November 17 – 19 in New York. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion at 12:40 p.m. ET on Tuesday, November 18.
• The Jefferies Global Healthcare Conference, being held November 18 – 20 in London, UK. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst-led discussion at 8:30 a.m. ET/1:30 p.m. Greenwich Mean Time on Tuesday, November 18.
• The Stephens Annual Investment Conference, being held November 18 – 20 in Nashville. Jason Garland, Chief Financial Officer, will participate in a series of one-on-one meetings with investors on Wednesday, November 19.

A live webcast of the conference presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.

Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
This email address is being protected from spambots. You need JavaScript enabled to view it.